Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Azelaprag [inn]
2. 4b8rej8zgy
3. Unii-4b8rej8zgy
4. 2049980-18-7
5. Amg 986
6. 2-pyrimidineethanesulfonamide, N-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4h-1,2,4-triazol-3-yl)-alpha,beta,5-trimethyl-, (alphas,betar)-
7. Amg986
8. Chembl4866732
9. Schembl18247065
10. Gtpl10061
11. Amg-986
12. Bdbm363380
13. Akos040741204
14. Us9845310, Example 506.0
15. Example 263 [wo2016187308a1]
16. Hy-109111
17. Cs-0077720
18. (2s,3r)-n-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4h-1,2,4-triazol-3-yl)-3-(5-methyl-2-pyrazinyl)-2-butanesulfonamide
19. (2s,3r)-n-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide
20. 2-pyrimidineethanesulfonamide, N-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4h-1,2,4-triazol-3-yl)-.alpha.,.beta.,5-trimethyl-, (.alpha.s,.beta.r)-
| Molecular Weight | 523.6 g/mol |
|---|---|
| Molecular Formula | C25H29N7O4S |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 9 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 142 |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 810 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BGE-105
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2024
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioAge Doses First Patient in Phase 2 Trial of Azelaprag for Obesity with Tirzepatide
Details : BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Brand Name : BGE-105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2024
Details:
Funding will support Phase II development of BioAge’s BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound for obesity treatment.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BGE-105
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Sofinnova Investments
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing February 13, 2024
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Sofinnova Investments
Deal Size : $170.0 million
Deal Type : Series D Financing
BioAge Raises $170 Million Series D for Obesity and Metabolic Disease Therapy
Details : Funding will support Phase II development of BioAge’s BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound for obesity treatment.
Brand Name : BGE-105
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 13, 2024
Details:
As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BGE-105
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2023
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.
Brand Name : BGE-105
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
